ABSTRACT. To learn more about the impact of intrathecal methotrexate and cystosine arabinoside therapy on neuronal metabolism, we measured serial cerebrospinal fluid concentrations of homovanillic acid and S-hydroxyindoleacetic acid, major metabolites of the neurotransmitters dopamine and serotonin, in children with acute lymphocytic leukemia. Multiple sequential cerebrospinal fluids were obtained from 30 children with acute lymphocytic leukemia evaluated prospectively from the time of diagnosis. We focused on the period of induction and intensification when children received weekly intrathecal chemotherapy. Paired cerebrospinal fluid specimens were also obtained at 3-month intervals from 60 children with acute lymphocytic leukemia in remission. Homovanillic acid and S-hydroxyindoleacetic acid were measured using high performance liquid chromatography with electrochemical detection. W e found that pretreatment metabolite values were no different from those in age-matched subjects in remission. In the first 5 wk of treatment, there were no significant changes in metabolite levels in patients treated exclusively with methotrexate. There was a transient decrease in homovanillic acid (-28 -C lo%, p < 0.001, Student's t test) and 5-hydroxyindoleacetic acid (-28 f 12%, p < 0.05) in five of six patients after a single intrathecal dose of cytosine arabinoside. In the next 4 wk there was a gradual rise in levels of homovanillic acid ( p = 0.001, by analysis of variance) and 5-hydroxyindoleacetic acid (p = 0.029, analysis of variance); this pattern did not correlate with administration of cranial irradiation. In children in remission, there were no significant changes in metabolite levels over a 3-month period. The data suggest that intensive therapy including methotrexate and cytosine arabinoside alters central neurotransmitter metabolism and/or transport in children with acute lymphocytic leukemia. (Pediatr Res 20: 285-291,1986) Abbreviations HVA, homovanillic acid 5 I-IIAA, 5-hydroxyindoleacetic acid DHFR, dihydrofolate reductase DHPR, dihydropteridine reductase ALL, acute lymphocytic leukemia CSF, cerebrospinal fluid MTX, methotrexate
ABSTRACT. To learn more about the impact of intrathecal methotrexate and cystosine arabinoside therapy on neuronal metabolism, we measured serial cerebrospinal fluid concentrations of homovanillic acid and S-hydroxyindoleacetic acid, major metabolites of the neurotransmitters dopamine and serotonin, in children with acute lymphocytic leukemia. Multiple sequential cerebrospinal fluids were obtained from 30 children with acute lymphocytic leukemia evaluated prospectively from the time of diagnosis. We focused on the period of induction and intensification when children received weekly intrathecal chemotherapy. Paired cerebrospinal fluid specimens were also obtained at 3-month intervals from 60 children with acute lymphocytic leukemia in remission. Homovanillic acid and S-hydroxyindoleacetic acid were measured using high performance liquid chromatography with electrochemical detection. W e found that pretreatment metabolite values were no different from those in age-matched subjects in remission. In the first 5 wk of treatment, there were no significant changes in metabolite levels in patients treated exclusively with methotrexate. There was a transient decrease in homovanillic acid (-28 -C lo%, p < 0.001, Student's t test) and 5-hydroxyindoleacetic acid (-28 f 12%, p < 0.05) in five of six patients after a single intrathecal dose of cytosine arabinoside. In the next 4 wk there was a gradual rise in levels of homovanillic acid ( p = 0.001, by analysis of variance) and 5-hydroxyindoleacetic acid (p = 0.029, analysis of variance); this pattern did not correlate with administration of cranial irradiation. In children in remission, there were no significant changes in metabolite levels over a 3-month period. The data suggest that intensive therapy including methotrexate and cytosine arabinoside alters central neurotransmitter metabolism and/or transport in children with acute lymphocytic leukemia. Inclusion of CNS prophylaxis in treatment protocols for ALL has contributed greatly to improved disease free survival rates. Intrathecal cytotoxic drugs-most commonly MTX or Ara-C with cranial irradiation-are routinely administered to childiren with no signs of CNS disease. However, clinical, radiologic, and pathologic evidence indicates that this treatment may produce neurotoxic side effects. The clinical spectrum of posttreatment sequelae includes behavior disorders, learning problems, seizures, and dementia (1 -10).
Acute, subacute, and chronic neurologic dysfunction have been attributed to I.T. methotrexate alone or in combination with cranial irradiation (3, 4, 6, (9) (10) (11) (12) . Transient headache, nausea, vomiting, meningismus, fever, and CSF pleocytosis occur within 12 h in 5-40% of patients and this acute toxic syndrome is thought to represent a chemical arachnoiditis (3) . Acute encephalopathy also occurs in a fraction of patients treated systemically with high dose MTX, suggesting that the drug may have direct acute metabolic effects on the brain (2) . Observations based on patients with toxic effects of acute intrathecal overdoses also support this proposition (13, 14) . Months to years after treatment, a progressive encephalopathy evolves in a few patients, especially those exposed to high doses of MTX (4, 7, 1 l , [15] [16] [17] . In these patients leukomalacia is seen on CAT scan of brain, and myelin basic protein, a myelin breakdown product, is usually elevated in spinal fluid during the active phase. Histopathologic examination of brain shows multifocal coagulative necrosis in white matter, as well as astrogliosis, demyelination, and dystrophic calcification (4, 16) . However, neuronal elements are also disrupted and axonal swelling has been described as an early finding (12, 17) . These effects are thought to be related directly to the cumulative dose of MTX administered (3, 4, 12) .
Considerable effort has been directed toward understanding methotrexate's effect on white matter but metabolic effects on neurons have received less attention. To examine toxicity of MTX, we measured serial CSF concentrations of metabolites for two biogenic amine neurotransmitters, dopamine and serotonin, in children before and during induction of therapy for ALL. Both transmitters are produced in the brain by rate limiting hydroxylation of precursor amino acids, a step that is dependent on adequate levels of tetrahydrobiopterin cofactor. Previous studies suggested that MTX might reduce concentrations of the pteridine hydroxylation cofactor by inhibiting its primary synthetic enzyme, DHPR, and also by reducing DHFR activity (1 [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Reduction in cofactor would be expected to reduce endogenous levels of dopamine and serotonin and their CSF metabolites, HVA and 5-HIAA (23, 24) .
Disruption in neurotransmitter synthesis might be associated with a variety of changes in appetite, behavior, attention, and level of consciousness (25) . We hypothesized that if MTX is able to inhibit neurotransmitter synthesis at toxic levels, it might produce more subtle but detectable changes in neurotransmitter metabolites in a general population of newly diagnosed leukemic children.
METHODS

Subjects.
One hundred sixty children age 1 to 21 yr, who attended the Pediatric Hematology-Oncology Clinic at The University of Michigan Medical Center between 1981 and 1984, were the subjects for this study ( Table 1 ). The protocol was approved by The University of Michigan Institutional Review Board.
Multiple sequential CSF's were obtained from 30 children (group 1) evaluated prospectively from the time of diagnosis of ALL. Pretreatment specimens were available along with samples from 2 to 9 wk after initiation of therapy in 26 of the 30. Four or more samples were obtained from the same patient in 26 cases. CSF was saved from fluid withdrawn during clinically indicated lumbar punctures. Although all patients received lumbar punctures and intrathecal therapy at similar time intervals, occasional CSF samples were lost to study because the small amount of fluid obtained was consumed by other clinically indicated examinations. None of the patients had CNS disease. At diagnosis, none had elevation of CSF protein. One patient had 33% blasts in his initial CSF but had only 1 white blood cell/mm3 and did not meet Children's Cancer Study Group criteria for CNS disease. No other patient had CSF pleocytosis or abnormal cytology. At most recent follow-up (mean duration of follow-up = 2 1 months) none of the 26 survivors had clinical evidence of treatment-induced encephalopathy. All were treated according to Children's Cancer Study Group protocols. During induction, systemic therapy included vincristine, prednisone, and L-asparaginase for all patients. In addition, a small number of patients received a single dose of cyclophosphamide or up to four doses of daunorubicin in induction. In the second or intensification phase, all patients were randomized to receive: 1) 6-mercaptopurine; or 2) thioguanine, Ara-C, L-asparaginase and oral methotrexate; or (3) Ara-C, cyclophosphamide, and 6-mercoptopurine.
All patients received seven doses of intrathecal drug during the induction and intensification phases of therapy: 24 of 30 received MTX (12 mg/MZ) alone, and six who were considered at high risk because of large peripheral leukemic cell burden received an intial dose of Ara-C (30-70 mg) followed by six doses of methotrexate (I2 mg/M2) (at lumbar puncture number 2, 4, 5, 6, 7, 8). Typically 2 wk elapsed between the first and second lumbar punctures, and the remainder were done at weekly intervals. Eighteen patients were begun on prophylactic cranial irradiation during the 4th or 5th wk of treatment. A second group of children who were in remission (group 2) were studied to determine variability in the CSF metabolites over several months. Two or more CSF specimens obtained at 3-month intervals were available from 60 children in this group, which included those who were no longer on treatment and others receiving maintenance I.T. MTX every three months. Multiple (up to 10) samples were available from some group 2 subjects.
A third group (group 3) was comprised of children in remission from leukemia, lymphoma or solid tumors from whom only a single CSF sample was obtained. Analysis of CSF. CSF was frozen at -20" C within an hour after withdrawal and stored at -70" C until the time of analysis. CSF levels of HVA and 5-HIAA were measured using high performance liquid chromatography with electrochemical detection (26) . Samples were thawed, spun in a microfuge (Beckman) for 1 min, and then 25 of the supernatant was injected directly into the chromatography system, which included a precolumn (Brownlee), a C-18, 5-11, reverse phase column (Altex), and electrochemical detector with glassy carbon electrode set at 0.8 V versus an Ag/AgCI electrode (Bioanalytical Systems). The mobile phase was 0.1 M phosphate-citrate buffer, pH 3, with 0.0001 M EDTA, and 0.012% sodium octyl sulfonate. Sodium octyl sulfonate was used because we also examined CSF dopamine levels (results not reported). HVA and 5-HIAA peaks were identified by calculation of retention times and the peaks of CSF metabolites coeluted with those of added standards. Concentrations were calculated by comparison with peak heights of external standards (Sigma).
Statistics. Statistical analysis of the data was canied out using the Michigan Interactive Data Analysis System. Where appropriate, HVA and 5-HIAA data were examined independently using Student's t test and least squares linear regression analysis with significance of the correlation determined by analysis of variance.
RESULTS
Children with acute leukemia are often systemically ill at the time of diagnosis and it was of interest to determine if their initial pretreatment HVA and 5-HIAA values were abnormal. Concentrations of both metabolites normally change markedly with age, declining by approximately 50% from birth to age 3 yr and diminishing sharply afterward until adolescence (27, 28) . Therefore, the pretreatment values in the patients (Figs. 1 and 2) were compared to values measured in age matched patients during remission (groups 2 and 3) and no significant difference was found (paired t tests). Furthermore, the leukemic patients' pretreatment values resembled closely our previous results from a large group of age-matched children who received lumbar punctures for a variety of reasons including surveillance of ALL in remission (28) . Their values also are close to results from other normal children (27) .
Inspection of the sequential data from group 1 patients during induction and intensification therapy (Figs. 1 and 2) suggested that HVA values followed a modestly downward trend over the first 5 wk, but rose over the next 4 wk. Linear regression analysis was performed separately on data from each period. Despite the trend downward, the linear correlation attempted on the early group of data was not statistically significant. In contrast, values from the 6th through the 9th wk did rise significantly (analysis of variance, p = 0.001). Data on 5-HIAA concentrations were very similar, remaining stable over the first 5 wk and then rising significantly from wk 6 through 9 (analysis of variance, p = 0.029). The data analyzed in Figures 1 and 2 included all data points gathered on the entire patient group, but independent analysis of individual data from 17 patients for whom it was possible to calculate early and late phase slopes yielded similar results. CNS prophylaxis in all these patients was started in similar fashion except that six of the 30 group 1 children received a single, initial dose of Ara-C instead of MTX. Excluding these patients from the statistical analysis of the early HVA and 5-HIAA data did not alter the results.
When the metabolites were measured 2 wk after the first dose of I.T. drug (Figs. 3 A and B could be related to any normalization of CSF dynamics by Ara-C theraw.
SAMPLES AT 3 MONTH INTERVALS
The k u l t s indicated that both HVA and 5-HIAA rose significantly only from wk 6-9 of treatment, and this prompted a search for variables that might be responsible for the effect. Eighteen patients received cranial irradiation beginning between wk 4 and 5, but elevated metabolite levels were also seen by wk 9 in patients who had not received this treatment. Type of systemic chemotherapy could not be related to the rise in metabolites. There was no relationship observed between elevation of CSF protein (in patients in both groups 1 and 2) and metabolite levels (e.g. patient 5 , Table 2 ).
There are few data available about the stability of neurotransmitter metabolite levels in an individual over time. To examine this issue, we evaluated paired specimens obtained 3 months apart in children in remission (Fig. 4) . Over this interval, values for HVA and 5-HIAA were remarkably stable. For example patient 1 (Table 2) , who had marked elevations returned to HVA and 5-HIAA values in remission that were nearly identical to pretreatment values.
Very few of the patients examined in these studies experienced sharp declines in CSF metabolites; data from three children are included in Table 2 . Patient 2 had a rapid and prominent fall in both HVA and 5-HIAA at two weeks after his first dose of I.T. Ara-C. Although he had no neurological signs at the time, 2 months later he developed a typical somnolence syndrome which resolved, leaving him normal at I yr follow-up. Patient #3 did have prominent somnolence, depression, and headache in asso- Table 2 ) had normal CSF metabolites, when studied 3 yr after she had received intensive I.T. MTX and cranial irradiation. Finally, the most dramatic reduction in CSF HVA was measured when a lumbar puncture was done in a patient in whom the spinal canal was blocked by neuroblastoma tumor (patient 6). Although neuroblastomas secrete HVA systemically (291, there is no evidence of significant blood to CSF transport of HVA. CSF HVA which is transferred primarily from the brain downward into the lumbar sac via CSF was markedly reduced. In contrast 5-HIAA, produced partially in the spinal cord, was preserved. Thus, the CSF block inverted the normal HVA/5-HIAA ratio.
DISCUSSION
These observations provide new information about CNS dopamine and serotonin metabolism in children with ALL undergoing treatment with systemic chemotherapy and intrathecal MTX or Ara-C. It is noteworthy that their pretreatment values were normal, since previous studies found early EEG abnormalities at this time (30, 31) . Although the respons'e to treatment has not been investigated before in a prospective fashion, an earlier report based on random CSF specimens from children already started on chemotherapy showed that monoamine metabolites were normal in most but were low in a few (32) . The reductions in that report seemed to correlate with the administration of I.T. MTX. Based on that preliminary data, as well as the possibility that MTX might inhibit brain dihydrofolate and dihydropteridine reductases, we hypothesized that monoamine metabolites might decline in these patients.
Temporary disruption in neurotransmitter synthesis might be associated with a variety of changes in appetite, behavior, attention, and level of consciousness (25) . This is supported by observations made in children with variant forms of phenylketonuria. In these patients, deficient pteridine cofactor production is associated with abnormalities in CSF neurotransmitter metabolites and neurologic deficts which respond in part to neurotransmitter replacement therapy (23, 33) . Similar replacement therapy had been suggested to treat toxic MTX encephalopathy (13, 18) . Therefore, the late elevation we observed in both HVA and 5-HlAA levels during wk 6-9 for the study group (group 1) was unexpected.
Based on the human data alone, it is impossible to decide whether the metabolites are elevated because of an increase in dopamine and serotonin turnover within central neurons or alternatively because their egress from CSF is impeded (25) . All patients received vincristine, prednisone, and L-asparaginase during induction. These drugs have no known direct effects on CNS neurotransmitter metabolism. By inhibition of protein synthesis, L-asparaginase could limit neurotransmitter production-but this was not observed. One way to determine if turnover was increased would be to measure levels after the acid transport system which removes the metabolites was blocked with probenecid (32) . However, this would be unsatisfactory since the drug frequently makes patients uncomfortable because of nausea and because probenecid may also inhibit removal of MTX from CSF (34, 35) . Alternatively, animal studies may provide insight into the effects of MTX. Our experiments with effects of infusions of MTX into the lateral ventricles of rhesus monkeys and rats suggest that the elevation in monoamine metabolites is caused by delayed egress rather than enhanced turnover (36, 37) . Constant infusion of MTX (0.05 mg/day for 5 days) into the lateral ventricle of monkeys produced a nearly 3-fold elevation in CSF concentrations of HVA compared with untreated controls and a smaller but significant rise in 5-HIAA (36) . However, direct brain tissue (corpus striatum) measurements of metabolites after repeated intraventricular injection of MTX in rats did not produce any significant elevation, suggesting a more distal site of accumulation (37) . While it remains possible that the CSF changes are related to some medication or combination of treatment other than intrathecal chemotherapy, the data from both humans and animals suggest that this component of therapy is capable of causing the changes we observed. Since daily CSF production is, normally, four to five times the total CSF volume, it is unlikely that the weekly or biweekly lumbar punctures would lead to altered metabolite concentrations unless CSF production was itself inhibited (for which there is no evidence).
Elevation in biogenic amine metabolites, independent of changes in neuronal metabolism, would not be expected to affect behavior or be neurotoxic. However, the observation has several other possible implications. MTX is eliminated from CSF by bulk flow and active transport, partially blockable by probenecid (34, (38) (39) (40) (41) (42) . If the elevated metabolites reflect a cumulative toxic reduction in function of the organic acid pump, then transit of other molecules, such as MTX itself, might be slowed. This would be reflected in a lengthening of CSF MTX elimination kinetics with prolonged or intensive treatment. This effect has not been reported but might be expected based on our data. It ib possible that chemotherapy may alter the egress of HVA and 5-HIAA through a subtle nonspecific inflammatory effect seen with MTX, or by a more specific biochemical action (1 5). Based on the absence of elevated CSF protein (data not shown) and absence of clinical symptoms of arachnoiditis in the patients, a specific biochemical effect seems more likely. If the changes noted reflect accumulation of metabolite in a probenecid-like fashion, possible depression in dopamine or serotonin turnover by a direct action would be partially masked unless allowance is made for the rising baseline.
We hypothesized that I.T. MTX might suppress biogenic amine metabolism if the drug reached a high enough concentration in lateral ventricular CSF bathing the caudate nuclei, regions of dense innervation by dopamine nerve terminals. Dopamine nerve terminals are the primary sites of tetrahydrobiopterin synthetic capacity and endogenous cofactor stores in the caudate and they are a major source of HVA in lumbar CSF (43, 44) . Clinical and animal studies suggest that the extent of entry of MTX into the lateral ventricles after lumbar injection is variable (38, 40, 41) . Two patients had marked reduction of CSF HVA during therapy. In both, there was at least one HVA value approximately 70% lower than values which preceded or followed them and both also had behavioral abnormalities noted by their attending physicians. In the case of the child in whom low HVA and 5-HIAA values occurred at the second and fourth lumbar puncture (patient 2, Table 2 ) during induction, a "soinnolence syndrome" was delayed several weeks. In the other (patient 3), the low HVA and 5-HIAA values were obtained at the time he was sleepy, depressed, and complaining of headaches 1 month after a dose of I.T. MTX. It is conceivable that such symptoms could be related to the neurochemical abnormalities. Dopamine and serotonin pathways send diffuse projections to multiple brain regions including the basal ganglia, cortex, and hypothalamus and disruptions in their metabolism have been linked to alterations in wakefulness, memory, appetite, activity, and attention (25) . Therefore the two cases lend some limited support to the proposition that biogenic amine abnormalities might be involved in certain temporary subacute encephalopathic signs and symptoms. The single patient with chronic severe leukoencephalopathy had normal metabolite levels, suggesting that chronic degeneration of these neurotransmitter pathways does not accompany the impressive destruction of myelinated areas. However, these findings do not exclude the possibility of preceding transient derangements of neurotransmitter metabolism.
It was unexpected that 1.T. Ara-C administration was associated with a fall in biogenic amine metabolites 2 wk later. The biochemical explanation for this is not clear since this drug has no known effect on biogenic amine metabolism. However, both MTX and Ara-C have been shown to produce a similar spectrum 290 SILVERSTEIN ET AL of acute and subacute neurotoxic effects as well as chronic leukoencephalopathy (1, 10). Although Ara-C is thought to act predominantly by inhibiting DNA polymerase, it also disrupts synthesis of RNA and protein (45, 46) . Like other pyrimidine antineoplastic drugs it causes neurotoxic effects in patients (47). MTX, in addition to its prominent effects on DNA synthesis, also inhibits protein synthesis and inhibits synthesis of the amino acids glycine and methionine, necessary for methyltransferase reactions (46) . Therefore, these two antimetabolites share a common action to disrupt protein synthesis in nondividing brain cells. Inhibition of protein synthesis needed for turnover and synthesis of essential myelin constituents, such as myelin basic protein, would be a rational mechanism by which they cause neurotoxic leukoencephalopathy. Reduction in biogenic amine synthesis might reflect a specific action of the drug on transmitter metabolism or a nonspecific toxic neuronal response to restricted protein synthesis.
Although neurotransmitter abnormalities may be involved in transient behavioral responses to CNS prophylaxis, their causal relationship to serious long-term leukoencephalopathy is tenuous. However, it is reasonable to consider whether transmitter metabolite levels could be used to assess the intensity of brain exposure to MTX. It is possible that transiently high ventricular concentrations might produce a prolonged effect on brain biochemical events through active polyglutamated storage forms of MTX (38) . Data from rat cultured pineal glands suggest that high MTX concentrations will reduce concentrations of tetrahydrobiopterin in brain (24) . MTX in concentrations that completely inhibited dihydrofolate reductase had no effect on levels of the cofactor but MTX concentrations in the range of M reduced tetrahydrobiopterin by 30%. Although this recent information suggests that DHFR activity plays little role in generating cofactor, high brain concentrations of MTX in a range that may be reached with certain treatment protocols, might be expected to suppress pteridine reductase. This is consistent also with our data from monkeys in which lower doses of MTX raised monoamine metabolite levels, but high dose continuous infusions produced marked reductions in association with transient encephalopathy (36) . Our human data do not make it clear if this phenomenon occurs in humans at clinically relevant doses. Further prospective longer term evaluation is warranted, especially in patients treated with high dose MTX who are at high risk for encephalopathy.
